Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$22.22M
EBITDA Margin
-7.62%
TTM Avg
-5.66%
3Y Avg
-2.78%
5Y Avg
-31.67%
Market Cap
$23.84M
EBITDA Margin
-99.97%
TTM Avg
-151.18%
3Y Avg
-217.30%
5Y Avg
-694.48%
Market Cap
$23.99M
EBITDA Margin
-701.04%
TTM Avg
-599.88%
3Y Avg
-518.61%
5Y Avg
-381.18%
Market Cap
$24.18M
EBITDA Margin
-883.91%
TTM Avg
-2536.80%
3Y Avg
-2479.09%
5Y Avg
-2025.77%
Market Cap
$21.05M
EBITDA Margin
-13586.02%
TTM Avg
-13586.02%
3Y Avg
-13586.02%
5Y Avg
-13586.02%
Market Cap
$25.24M
EBITDA Margin
-710238.40%
TTM Avg
-369696.29%
3Y Avg
-185511.92%
5Y Avg
-193923.76%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $22.85M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.36M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.22M | -7.62% | -5.66% | -2.78% | -31.67% |
| Modular Medical, Inc. (MODD)vs › | $21.93M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.84M | -99.97% | -151.18% | -217.30% | -694.48% |
| Kyntra Bio, Inc. (KYNB)vs › | $23.99M | -701.04% | -599.88% | -518.61% | -381.18% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | -883.91% | -2536.80% | -2479.09% | -2025.77% |
| Quantum BioPharma Ltd. (QNTM)vs › | $21.05M | -13586.02% | -13586.02% | -13586.02% | -13586.02% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $25.24M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
| InspireMD, Inc. (NSPR)vs › | $25.30M | -541.66% | -507.83% | -427.73% | -407.72% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
